![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CM O'Hara, A Uhland-Smith, KL O'Malley and RD Todd
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
The goal of the current study was to determine which of the D2-like receptors (D2, D3 or D4) are involved in autoreceptor regulation of dopamine synthesis. We have derived a model system utilizing a mouse mesencephalic cell line, MN9D, which both synthesizes and releases dopamine, to characterize the modulation of tyrosine hydroxylase activity, the rate limiting enzyme in the conversion of tyrosine to dopamine, by the D2-like receptors. Previously, we have shown that stimulation of D2 and D3, but not D4, dopamine receptors transfected into MN9D cells inhibited the release of dopamine. In the current study, we show that quinpirole stimulation of transfected D2 and D3, but not D4, dopamine receptors inhibited K+-stimulated tyrosine hydroxylase activity in a pertussis toxin-sensitive manner, strongly suggesting G-protein coupling as a mechanistic pathway. The D2 receptor effect could be maintained for at least 60 min, whereas the D3 receptor effect desensitized. Treatment with 10 microM forskolin, which raises cyclic AMP levels or with 100 nM okadaic acid, a potent phosphatase inhibitor, had no effect on the D2-or D3-mediated inhibition, suggesting that these effects may be independent of both cyclic AMP- and okadaic acid-sensitive phosphatase activity. Taken together, these data confirm the hypothesis that dopamine D2 and D3 receptors can perform dual roles in autoreceptor regulation.
This article has been cited by other articles:
|
|
 |
|
  A. Nikoshkov, K. Drakenberg, X. Wang, M. Cs. Horvath, E. Keller, and Y. L. Hurd Opioid neuropeptide genotypes in relation to heroin abuse: Dopamine tone contributes to reversed mesolimbic proenkephalin expression PNAS, January 15, 2008; 105(2): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Schmitz, C. Schmauss, and D. Sulzer Altered Dopamine Release and Uptake Kinetics in Mice Lacking D2 Receptors J. Neurosci., September 15, 2002; 22(18): 8002 - 8009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Kilts, H. S. Connery, E. G. Arrington, M. M. Lewis, C. P. Lawler, G. S. Oxford, K. L. O'Malley, R. D. Todd, B. L. Blake, D. E. Nichols, et al. Functional Selectivity of Dopamine Receptor Agonists. II. Actions of Dihydrexidine in D2L Receptor-Transfected MN9D Cells and Pituitary Lactotrophs J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Perez, J. C. Waymire, E. Lin, J. J. Liu, F. Guo, and M. J. Zigmond A Role for alpha -Synuclein in the Regulation of Dopamine Biosynthesis J. Neurosci., April 15, 2002; 22(8): 3090 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Stanwood, R. P. Artymyshyn, M.-P. Kung, H. F. Kung, I. Lucki, and P. McGonigle Quantitative Autoradiographic Mapping of Rat Brain Dopamine D3 Binding with [125I]7-OH-PIPAT: Evidence for the Presence of D3 Receptors on Dopaminergic and Nondopaminergic Cell Bodies and Terminals J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1223 - 1231. [Abstract] [Full Text]
|
|
|
|
|
|
J. Diaz, C. Pilon, B. Le Foll, C. Gros, A. Triller, J.-C. Schwartz, and P. Sokoloff Dopamine D3 Receptors Expressed by All Mesencephalic Dopamine Neurons J. Neurosci., December 1, 2000; 20(23): 8677 - 8684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Morón, V. Pérez, M. Pastó, J. M. Lizcano, and M. Unzeta FA-70, A Novel Selective and Irreversible Monoamine Oxidase-A Inhibitor: Effect on Monoamine Metabolism in Mouse Cerebral Cortex J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 788 - 794. [Abstract] [Full Text]
|
|
|
|
|
|
J. F. M. Vanhauwe, N. Fraeyman, B. J. B. Francken, W. H. M. L. Luyten, and J. E. Leysen Comparison of the Ligand Binding and Signaling Properties of Human Dopamine D2 and D3 Receptors in Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 908 - 916. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, A. Newman-Tancredi, M. Brocco, A. Gobert, F. Lejeune, V. Audinot, J.-M. Rivet, R. Schreiber, A. Dekeyne, M. Spedding, et al. S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 167 - 186. [Abstract] [Full Text]
|
|
|
|
|
|
V. Audinot, A. Newman-Tancredi, A. Gobert, J.-M. Rivet, M. Brocco, F. Lejeune, L. Gluck, I. Desposte, K. Bervoets, A. Dekeyne, et al. A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3 Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194 J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 187 - 197. [Abstract] [Full Text]
|
|
|
|
|
|
T. E. Koeltzow, M. Xu, D. C. Cooper, X.-T. Hu, S. Tonegawa, M. E. Wolf, and F. J. White Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3 Receptor Mutant Mice J. Neurosci., March 15, 1998; 18(6): 2231 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Levant The D3 Dopamine Receptor: Neurobiology and Potential Clinical Relevance Pharmacol. Rev., September 1, 1997; 49(3): 231 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Watts and K. A. Neve Activation of Type II Adenylate Cyclase by D2 and D4 but Not D3 Dopamine Receptors Mol. Pharmacol., August 1, 1997; 52(2): 181 - 186. [Abstract] [Full Text]
|
|
|
|
|
|
A. Newman-Tancredi, V. Audinot, C. Chaput, and L.V. a. M. J. Millan [35S]Guanosine-5'-O-(3-thio)triphosphate Binding as a Measure of Efficacy at Human Recombinant Dopamine D4.4 Receptors: Actions of Antiparkinsonian and Antipsychotic Agents J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 181 - 191. [Abstract] [Full Text]
|
|
|
|
|
|
R. D. Todd, J. Carl, S. Harmon, K. L. O'Malley, and J. S. Perlmutter Dynamic Changes in Striatal Dopamine D2 and D3 Receptor Protein and mRNA in Response to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Denervation in Baboons J. Neurosci., December 1, 1996; 16(23): 7776 - 7782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Park, S. A. Sedore, C. Cronmiller, and J. Hirsh Type II cAMP-dependent Protein Kinase-deficient Drosophila Are Viable but Show Developmental, Circadian, and Drug Response Phenotypes J. Biol. Chem., June 30, 2000; 275(27): 20588 - 20596. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
